

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 30 November 2015 – On 29 October 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 17.5 billion to be executed during a 12-month period beginning 30 January 2015.

Under the programme initiated 29 October 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 4.5 billion in the period from 29 October 2015 to 1 February 2016.

Since the announcement as of 23 November 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	3,450,000		1,289,513,566
23 November 2015	200,000	380.66	76,132,180
24 November 2015	180,000	374.70	67,445,622
25 November 2015	175,000	382.43	66,925,023
26 November 2015	205,000	385.67	79,061,715
27 November 2015	185,000	385.31	71,281,629
Accumulated under the programme	4,395,000		1,650,359,733

With the transactions stated above, Novo Nordisk owns a total of 48,884,703 B shares of DKK 0.20, corresponding to 1.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,600,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17.5 billion during a 12-month period beginning 30 January 2015. As of 27 November 2015, Novo Nordisk has repurchased a total of 40,298,251 B shares equal to a transaction value of DKK 14,650,359,223.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

Further information

Media:

Anne Margrethe Hauge	+45 3079 3450	amhg@novonordisk.com
----------------------	---------------	--

Investors:

Peter Hugrefte Ankersen	+45 3075 9085	phak@novonordisk.com
Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Melanie Raouzeos	+45 3075 3479	mrz@novonordisk.com
Kasper Veje	+45 3079 8519	kpvj@novonordisk.com
Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com